/KNE.V
KNE.V Stock - Kane Biotech Inc.
Healthcare|BiotechnologyTSXV
$0.04+0.00%
+$0.00 (+0.00%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.04
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KNE.V
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.03 – $0.04
TARGET (TP)$0.04
STOP LOSS$0.03
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.18
52W High$0.12
52W Low$0.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.08M | $148,980 | $156,733 | $1.61M | $1.34M |
| Gross Profit | $872,096 | $109,470 | $1.41M | $568,441 | $526,859 |
| Gross Margin | 41.9% | 73.5% | 901.7% | 35.4% | 39.3% |
| Operating Income | $-4,493,953 | $-3,357,386 | $-3,457,605 | $-4,883,557 | $-4,224,373 |
| Net Income | $-3,024,507 | $-5,034,103 | $-3,889,892 | $-4,604,566 | $-3,716,686 |
| Net Margin | -145.3% | -3379.0% | -2481.9% | -286.4% | -277.0% |
| EPS | $-0.02 | $-0.04 | $-0.03 | $-0.04 | $-0.03 |
Company Overview
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KNE.VBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q4 2025 | Nov 28, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 27, 2025 | — | $-0.00 | — | — |
Q2 2025 | Apr 28, 2025 | — | $-0.01 | — | — |
Q1 2025 | Mar 28, 2025 | — | $0.00 | — | — |
Q4 2024 | Nov 26, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 29, 2024 | — | $0.06 | — | — |
Q2 2024 | May 23, 2024 | — | $-0.01 | — | — |
Q1 2024 | Mar 26, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 28, 2023 | — | $-0.01 | — | — |
Q3 2023 | Aug 29, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 25, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 27, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 24, 2022 | — | $-0.01 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about KNE.V
What is KNE.V's current stock price?
Kane Biotech Inc. (KNE.V) is currently trading at $0.04 per share. The stock has moved +0.00% today.
What is the analyst price target for KNE.V?
No analyst price targets are currently available for this stock.
What sector is Kane Biotech Inc. in?
Kane Biotech Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSXV exchange.
What is KNE.V's market cap?
Kane Biotech Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does KNE.V pay dividends?
No, Kane Biotech Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPLI.TO
Appili Therapeutics Inc.
$0.02
Mkt Cap: $0.0B
APS.TO
Aptose Biosciences Inc.
$2.08
Mkt Cap: $0.0B
AVCR.V
Avricore Health Inc.
$0.05
Mkt Cap: $0.0B
CANB.V
CanadaBis Capital Inc.
$0.03
Mkt Cap: $0.0B
HEAL.CN
Restart Life Sciences Corp.
$0.11
Mkt Cap: $0.0B
MVMD.CN
Mountain Valley MD Holdings Inc.
$0.01
Mkt Cap: $0.0B
TELO.V
Telo Genomics Corp.
$0.05
Mkt Cap: $0.0B
TGIF.CN
1933 Industries Inc.
$0.01
Mkt Cap: $0.0B
THRM.V
Therma Bright Inc.
$0.04
Mkt Cap: $0.0B
XRTX.V
XORTX Therapeutics Inc.
$0.85
Mkt Cap: $0.0B
Explore stocks similar to KNE.V for comparison